RoslinCT, a leading Contract Development and Manufacturing Organization (CDMO) focused on advanced cell therapies, announces investment from Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare.

Established in 2006 in Edinburgh, Scotland, with support from Scottish Enterprise, RoslinCT was formed through an initial spin-out from the Roslin Institute, which has a famous track record in genetic and cellular biology. Since 2014, the company has had a manufacturing base within the University of Edinburgh’s Centre for Regenerative Medicine in a facility shared with the Scottish National Blood Transfusion Service. RoslinCT has worked to advance the field of regenerative medicine and today is at the forefront of high-quality cell therapy development and manufacturing. The company recently expanded into facilities at the Edinburgh BioQuarter, and is recognised globally as a unique CDMO establishing its own commercial scale production.


View the full story here.